Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

M Roussel, J Ferrant, F Reizine, S Le Gallou, J Dulong, S Carl, M Lesouhaitier, M Gregoire, N Bescher, C Verdy, M Latour, I Bézier, M Cornic, A Vinit, C Monvoisin, B Sawitzki, S Leonard, S Paul, J Feuillard, R JeannetT Daix, Vijay K. Tiwari, J M Tadié, M Cogné, K Tarte

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
95 Downloads (Pure)


Acute respiratory distress syndrome (ARDS) is the main complication of COVID-19, requiring admission to Intensive Care Unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS differs from other causes of ARDS remains unknown. To address this question, we build 3 cohorts of patients categorize in COVID-19 ARDS , COVID-19 ARDS , and COVID-19 ARDS , and compare their immune landscape analyze by high-dimensional mass cytometry on peripheral blood. A cell signature associating S100A9/calprotectin-producing CD169 monocytes, plasmablasts, and Th1 cells is found in COVID-19 ARDS , unlike COVID-19 ARDS patients. Moreover, this signature is essentially share with COVID-19 ARDS patients, suggesting that severe COVID-19 patients, whatever they experience or not ARDS, display similar immune profiles. We show an increase in CD14 HLA-DR and CD14 CD16 monocytes correlate to the occurrence of adverse events during ICU stay. We demonstrate that COVID-19-associated ARDS display a specific immune profile, and might benefit from personalize therapy in addition to standard ARDS management.
Original languageEnglish
Article number100291
Number of pages18
JournalCell Reports Medicine
Early online date06 May 2021
Publication statusPublished - 15 Jun 2021


Dive into the research topics of 'Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection'. Together they form a unique fingerprint.

Cite this